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ABSTRACT
We evaluated the effect of tailoring treatments based on predictions informed 
by tumor molecular profiles across a range of cancers, using data from Caris Life 
Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital 
tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian 
surface epithelial carcinomas, and urinary tract cancers.
Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing 
for tumors from 841 patients had been previously used to recommend treatments; 
some physicians followed the suggestions completely while some did not. This 
information was assessed to find out if the outcome was better for the patients where 
their received drugs matched recommendations.
The IHC biomarker for the progesterone receptor and for the androgen receptor 
were found to be most prognostic for survival overall. The IHC biomarkers for 
P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair 
protein ERCC1 were also shown to be significant predictors of outcome. Patients 
whose treatments matched those predicted to be of benefit survived for an average of 
512 days, compared to 468 days for those that did not (P = 0.0684). In the matched 
treatment group, 34% of patients were deceased at the completion of monitoring, 
whereas this was 47% in the unmatched group (P = 0.0001). 
INTRODUCTION
Cancer is a disease of tissue growth deregulation 
that causes approximately 15% of deaths globally, which 
was about 8 million in 2012 [1, 2]. Germline mutations 
drive only around 1 percent of tumors [3]. Multistep 
tumorigenesis occurs through consecutive changes, that 
include mutations in oncogenes, epigenetic silencing of 
tumor suppressor genes, and chromosomal aberrations. 
These changes underlie the causes of cancer, along 
with heterotypic interactions between the tumor and its 
microenvironment, conferring a selective advantage 
leading to clonal expansion. A typical breast or colon 
carcinoma will have 60 to 70 mutations, of which about 
three or four may drive this expansion, while the others 
may be viewed as passengers [4].
Guided treatments via molecular characterization 
of solid tumors using biomarkers such as 
immunohistochemistry (IHC) and genomic sequencing 
has resulted in better outcomes in subsets of patients, such 
as those with EGFR (epidermal growth factor receptor) 
mutant lung cancer and BRAF mutant melanoma [5]. 
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Many organizations are now providing molecular profiling 
platforms to clinicians to guide therapeutic decisions in the 
context of metastatic and early disease. Platforms such as 
Oncotype DX, Foundation One, EndoPredict and Caris 
Life Sciences’ Molecular Intelligence are commercially 
available, and are used in routine clinical practice in the UK 
and the USA. Elsewhere, the American Society of Clinical 
Oncology (ASCO) launched CancerLinQ in 2015, which 
uses records from thousands of oncology treatment centers 
to improve patient care, by recommending treatment plans 
using this information. The Oncology Research Information 
Exchange Network (ORIEN), which has been initiated by 
the Moffitt Cancer Center, uses clinical data and tissue 
samples in a similar way. IBM’s Watson Health is also using 
clinical data to aid the design of cancer therapy plans.
Here we used data from Caris Life Sciences to see if 
tumor molecular profiling led to better clinical of outcome 
when used to give treatment recommendations.
RESULTS
Patient characteristics
Data describing clinical outcomes for patients 
with a range of cancer types was assessed to see if there 
was a benefit when their treatment regimens adhered to 
recommendations that utilized tumor molecular profiling 
to select drugs. In the matched treatment set, patients were 
given at least one recommended drug after collection for 
tumor profiling and none that were not. In the unmatched 
set one or more drugs that were predicted to lack benefit 
were in the treatment plan. The matched group consisted of 
438 patients and the unmatched 403 patients. Patients and 
their primary tumors are summarized in Tables 1 and 2.
Treatment analysis
The individual treatments for the patients are shown 
for the two groups in Figure 1. There are 438 matched 
and 403 unmatched patients represented by a vertical line 
for each. Green shows drugs of benefit, red is a drug that 
lacks benefit, and yellow is both of these types of drug at 
the same time.
Table 3 shows the frequency of drugs given. The 
number of patients treated with a drug is shown in the first 
column, and the number of continuous treatment periods 
is shown in all other columns, i.e. treatments of the same 
patient with intervening periods are counted separately. 
The drugs given to the most number of patients were 
carboplatin (513 patients), paclitaxel (425), bevacizumab 
(215), gemcitabine hydrochloride (203), docetaxel (196), 
and cisplatin (186). The most common drugs by counting 
continuous treatments were carboplatin (given for 701 
periods of time), paclitaxel (556), bevacizumab (310), 
fluorouracil (242), gemcitabine hydrochloride (241), 
docetaxel (223), and cisplatin (214 times).
On average patients received 4.8 drugs (counting 
separate treatment periods). Of these, 45% were of benefit, 
19% lacked benefit, and 36% neither of these types. 
Matched patients had 4.2 treatments on average – 60% of 
these were expected to be of benefit, 3% lacked benefit. 
Unmatched patients had an average of 5.5 drugs; 32% of 
these were of benefit, 33% lacking benefit.
The drugs of benefit given most often were 
carboplatin (339 treatments), paclitaxel (326), fluorouracil 
(160), gemcitabine hydrochloride (112), docetaxel (108), 
and cisplatin (104).
The treatments that were profiled to lack benefit 
given most often were carboplatin (162 periods of time), 
paclitaxel (93), gemcitabine hydrochloride (67), and 
cisplatin (61).
In the matched group 37% had no associated 
recommendation i.e. neither of type benefit or lack of 
benefit, and 35% in the unmatched group. The most popular 
in the neither category was bevacizumab (given 235 times), 
followed by carboplatin (194), leucovorin calcium (148), 
paclitaxel (129), and cyclophosphamide (103).
We identified off-label use of ER, PR & AR 
associated therapies, but this only occurred in two of the 
841 patients; although they had 100% survival, it is not 
possible to draw conclusions from this due to the small 
number of patients.
We looked for potentially actionable mutations that 
were in the tumour profile, and corresponding treatments, 
using the following types. 
BRAF mutations in melanoma, colorectal, NSCLC 
and cholangiocarcinoma cohorts, with  treatment using 
sorafenib tosylate or regorafenib.
EGFR mutations in NSCLC and glioblastomas, 
treated with erlotinib hydrochloride, afatinib dimaleate, or 
lapatinib ditosylate.
ERBB2 mutations in breast, ovarian, NSCLC and 
gastroesophageal, with afatinib dimaleate or lapatinib 
ditosylate.
FGFR1 mutations in lymphoma using regorafenib or 
pazopanib hydrochloride.
FGFR2 mutations in gastroesophageal, NSCLC or 
female genital tract with regorafenib.
PDGFRA mutations in glioblastoma, treated with 
regorafenib, sunitinib malate or pazopanib hydrochloride.
RET mutations in adrenal cortical carcinoma or 
NSCLC, using cabozantinib-s-malate, sorafenib tosylate, 
regorafenib or sunitinib malate.
ALK mutations in NSCLC treated with crizotinib.
From this, We found 67 examples of clearly 
actionable mutations in 59 patients (35 were unmatched 
treatment patients, 24 were matched). There were at most 
two actionable mutations in any patient. Nine patients 
out of the 59 (15%) actually received a therapy clearly 
specific to the mutation; these all used regorafenib to treat 
colorectal patients with BRAF mutations. These nine 
patients had a mortality rate of 55%, an average survival 
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after diagnosis (include those that died and those that 
were still alive when records finished) of 1202.7 days, 
and a post-profiling time on record of 385.7 days. The 
mortality rate here is worse than the colorectal cohort’s 
average, as is the time of monitoring after profiling, but 
the time of recorded monitoring after diagnosis is longer 
than the average.
We investigated if there was an improvement 
in outcome when treatments occur at the same time, 
irrespective of whether they were categorized as matched 
or unmatched. Figure 2 shows plots for the change in 
survival when overlapping treatment days increases 
(days were counted for each pair of overlapping 
treatments in each patient, so that for example, if 
three drugs were given at the same time, the overlap 
time was counted twice). We assessed the “all cohorts 
combined”  dataset, and also the breast, colorectal, 
female genital tract malignancy and NSCLC cohorts 
Figure 1: Shown above are treatment plans for 438 matched patients, and in the lower plot treatment plans for 403 unmatched 
patients. The y-axis is time in days and zero is the time of tumor profiling, so that they are ordered by increasing post-profiling survival 
time. Dark gray is total time monitored from diagnosis, and this ends either in last follow-up or when the patient is deceased; a black line 
at the top of a column indicates death. Green is time on a treatment expected to be of benefit, red is treatment expected to lack benefit, and 
yellow is a combined therapy that uses drugs profiled to be both of benefit and to lack benefit. Blue is a neutral therapy that has neither 
associated prediction of benefit nor lack of benefit. Please note that a small number of treatment plans are not shown from their start (i.e. are 
incomplete at their base) for the purpose of brevity; the maximum time before collection for profiling was 11,673 days.
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separately. There does appear to be an improvement 
overall when giving treatments simultaneously for breast 
and colorectal, as shown in Figure 2. For the female 
genital tract malignancy and NSCLC cohorts, there is an 
improvement as the amount of time that drugs are given 
concurrently increases, but this later decreases, although 
this is outside the main body of points that each represent 
a patient. This is also the case in the all cohorts combined 
plot shown in Figure 2A) i.e. an initial improvement tails 
off and then slightly decreases for a small number of 
patients with the highest total overlap times. The upper-
right plot, Figure 2B), shows a subset of patients from 
the all cohorts dataset, restricting to those with total 
overlap time of 1000 days or less, and 2500 days survival 
after diagnosis or less, so as to zoom in on the lower-left 
of the plot shown in Figure 2A). We further analyzed the 
data to see if this could be explained by categorizing the 
overlapping treatments, using a variety of classes such 
as chemotherapy, hormonal therapies, different types 
of targeted therapies excluding monoclonal antibodies 
(e.g. kinase inhibitors, etc.), monoclonal antibodies, and 
others. However, we did not find a clearly better way of 
combining therapies when looking at the outcome data 
in this way. Similarly, we did not find a distinctly better 
sequence of treatments i.e. where one class of therapy 
was given before another.
Table 1: Cancer cohorts present in the Caris data used here, the number of patients that are 
present in them, and how each cohort can be divided into patients whose treatments matched 
those that were recommended based on a molecular profile of their tumor, and those whose did 
not
Cohort Matched Unmatched Total
Adrenal cortical carcinoma - 1 1
Anal cancer 1 3 4
Breast carcinoma 43 49 92
Cholangiocarcinoma 5 1 6
Colorectal adenocarcinoma 42 53 95
CUP 1 8 9
Epithelial skin cancer 1 1 2
Female genital tract malignancy 64 48 112
Gastroesophageal adenocarcinoma 8 15 23
Glioblastoma 4 1 5
Head and neck squamous carcinoma 5 6 11
Leiomyosarcoma 9 5 14
Liver hepatocellular carcinoma 2 1 3
Lung bronchioloalveolar carcinoma (BAC) - 1 1
Lung non-small-cell lung cancer (NSCLC) 42 49 91
Lymphoma 2 - 2
Major and minor salivary glands 3 - 3
Melanoma 3 4 7
Neuroblastoma - 1 1
Neuroendocrine tumors 13 10 23
Non epithelial ovarian cancer (non EOC) 2 2 4
Ovarian surface epithelial carcinomas 154 115 269
Pancreatic adenocarcinoma 7 9 16
Paragangliomas 1 - 1
Prostatic adenocarcinoma 2 1 3
Small intestinal malignancies - 1 1
Soft tissue tumors 7 10 17
Urinary tract 16 8 24
Uveal melanoma 1 - 1
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Patient survival
In the matched group 34% of patients died 
compared to 47% of the unmatched group of patients. 
Figure 3 shows a Kaplan-Meier curve of overall survival 
for patients treated only with therapies predicted to be 
beneficial, compared to those of the unmatched treatment 
group. Figure 3 also shows biomarker differences between 
Figure 2: Comparison of survival with number of overlapping treatment days for (A) all cohorts combined of which (B) zooms into the 
lower-left of, (C) breast carcinoma, (D) colorectal adenocarcinoma, (E) female genital tract malignancy and (F) NSCLC cohorts. Days 
were counted for each pair of overlapping treatments. The blue line is a loess curve that combines linear least squares regression with 
nonlinear regression to provide a smooth curve through the points. The gray band surrounding the blue curve is it’s 95% confidence interval. 
Points are colored to represent mortality: red denotes death of the patient, green represents no death by the end of monitoring.
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Table 2: Patient ages for the matched and unmatched treatment groups
Age Matched Unmatched
20–29 3 7
30–39 16 11
40–49 54 51
50–59 111 105
60–69 130 124
70–79 106 81
80–89 18 24
Figure 3: Clockwise from upper-left: Status of biomarkers contrasted between the matched and unmatched treatment groups where 
“positive ratio” is the percentage that have positive biomarker results - positive indicates protein expression above a predefined 
threshold in IHC markers for example, and for sequencing markers positive denotes a gene mutation that is usually pathogenic. 
The size of the circle indicates the number of cases. Upper-right to lower-right: survival time, treatment numbers, and grade of samples are 
summarized. Lower-left: a Kaplan-Meier plot of survival time for patients treated with recommended therapies only, compared to patients 
who had at least one therapy that had been predicted to have no benefit i.e. matched versus unmatched.
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the matched and unmatched groups, and summaries of 
survival, treatment and sample information. Table 4 shows 
a summary of the differences in survival between some of 
the larger cancer categories available in the data analyzed 
here, along with biomarkers and drugs given most often 
for those cancer subsets.
Predictive biomarkers
The IHC biomarkers that were good predictors for 
survival (Figure 4) were the estrogen receptor (ER) (in 
ovarian surface epithelial carcinomas and breast carcinomas), 
progesterone receptor (PR) (in breast carcinomas, female 
Table 4: Comparison of some of the major cohorts in the Caris CODE database
Cohort
Total Number of Patients 
(Matched Patients; 
Unmatched Patients)
Post Profiling Survival 
in Days – Matched vs 
Unmatched 
Mortality – 
Matched vs 
Unmatched
Significant Biomarkers Most Frequent Drugs
Breast 92 (43; 49) 667 vs 510 (P = 0.03) 26% vs 41%  
(P = 0.13)
AR, ER, PR cyclophosphamide, doxorubicin 
hydrochloride, docetaxel
Colorectal 95 (42; 53) 442 vs 541 (P = 0.1773) 19% vs 49%  
(P = 0.0022)
TS (thymidylate synthase) fluorouracil, leucovorin calcium, 
oxaliplatin
Female genital tract 112 (64; 48) 593 vs 449 (P = 0.03) 30% vs 40% 
(P = 0.28)
PR carboplatin, paclitaxel, cisplatin
Lung 91 (42; 49) 402 vs 382 (P = 0.79) 48% vs 53% 
(P = 0.61)
ERCC1, EGFR carboplatin, pemetrexed disodium, 
docetaxel
All cancers 
combined 
(including others)
841 (438; 403) 512 vs 468 (P = 0.07) 34% vs 47%  
(P = 0.0001)
PR, AR, PGP 
(P-glycoportein), cMET, 
ERCC1
carboplatin, paclitaxel, 
bevacizumab
Table 3: Drugs given most often in the matched and unmatched treatment groups and the drugs 
given most frequently that were profiled to be beneficial, lacking benefit, or neither
Number of 
Patients Treated
Most Frequently Administered Drugs (Total Treatment Periods)
All Patients 
Treated
All Patients 
– Treatment 
Periods
Matched Only 
Patients, All 
Treatments
Matched, After 
Profiling Treatments 
Only
Unmatched 
Patients, All 
Treatments
Unmatched, After 
Profiling Treatments 
Only
Drugs 
Predicted of 
Benefit
Drugs 
Predicted to 
Lack Benefit
Drugs with No 
Prediction (Neither 
of Benefit or Lack of 
Benefit)
carboplatin – 513 
patients
carboplatin  = 701 carboplatin  = 
361
carboplatin  = 166 carboplatin  = 340 carboplatin  = 120 carboplatin  
= 339
carboplatin  
= 162
bevacizumab = 235
paclitaxel – 425 
patients
paclitaxel = 556 paclitaxel = 291 paclitaxel = 129 paclitaxel = 265 bevacizumab = 92 paclitaxel = 326 paclitaxel = 93 carboplatin  = 194
bevacizumab 215 – 
patients
bevacizumab 
= 310
bevacizumab 
= 119
bevacizumab = 69 bevacizumab = 191 paclitaxel = 90 fluorouracil 
= 160
gemcitabine 
hydrochloride 
= 67
leucovorin calcium 
= 148
gemcitabine 
hydrochloride 203 
– patients
fluorouracil = 242 docetaxel = 118 docetaxel = 49 fluorouracil = 168 gemcitabine 
hydrochloride = 79
gemcitabine 
hydrochloride 
= 112
cisplatin  = 61 paclitaxel = 129
docetaxel – 196 
patients
gemcitabine 
hydrochloride 
= 241
gemcitabine 
hydrochloride 
= 101
gemcitabine 
hydrochloride = 48
gemcitabine 
hydrochloride 
= 140
fluorouracil = 68 docetaxel = 108 doxorubicin 
hydrochloride 
= 53
cyclophosphamide 
= 103
cisplatin – 186 
patients
docetaxel = 223 cisplatin  = 100 cisplatin  = 40 cisplatin  = 114 cisplatin  = 45; 
leucovorin calcium 
= 45
cisplatin  = 104 fluorouracil 
= 45
docetaxel = 67
fluorouracil – 143 
patients
cisplatin  = 214 fluorouracil = 74 capectabine = 25; 
fluorouracil = 25
leucovorin calcium 
= 106
- doxorubicin 
hydrochloride 
= 79
docetaxel = 44 gemcitabine 
hydrochloride = 59
doxorubicin 
hydrochloride 136 
– patients
leucovorin calcium 
= 156
doxorubicin 
hydrochloride 
= 72
- docetaxel = 105 docetaxel = 39 bevacizumab 
= 68
irinotecan 
hydrochloride 
= 43
capecitabine = 50
oxaliplatin – 116 
patients
doxorubicin 
hydrochloride = 
144; oxaliplatin  
= 146
oxaliplatin  = 55 doxorubicin 
hydrochloride = 24
oxaliplatin  = 91 irinotecan 
hydrochloride = 35
pegylated 
liposomal 
doxorubicin 
hydrochloride 
= 67
oxaliplatin  
= 35
cisplatin  = 46
cyclophosphamide 
– 101 patients
- leucovorin 
calcium = 50
pegylated liposomal 
doxorubicin 
hydrochloride = 22
doxorubicin 
hydrochloride = 74
pegylated liposomal 
doxorubicin 
hydrochloride = 32
oxaliplatin  = 64 topotecan 
hydrochloride 
18
oxaliplatin  = 38
(Number of patients that received a drug is shown in the first column; number of treatments i.e. continuous periods of receiving a drug is shown in all other columns).
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genital tract malignancies, and ovarian surface epithelial 
carcinomas) and androgen receptor (AR) (in breast 
carcinoma), along with those for P-glycoprotein (PGP) (no 
specific cohort), tyrosine-protein kinase Met (cMET) (no 
specifc cohort) and the DNA excision repair protein ERCC1 
(in NSCLC). The best sequencing biomarker was for the 
epidermal growth factor receptor gene (in NSCLC), but it 
was less significant (P = 0.0764) than the best IHC markers. 
Further information about the biomarkers identified to be 
most prognostic for patient survival is shown in Figures 5, 
6 and 7 (ER, PR and AR IHCs respectively). Although they 
did not stand out as significant across the background of 
all cohorts, TOPO1 was a significant predictor of outcome 
within the ovarian patients, as was TS (thymidylate synthase) 
for colorectal patients. If breast cancer patients are removed 
from the set of all other patients analysed here, ER and PR 
Figure 4: Volcano plots of biomarkers’ prognostic values. In the plot shown above, several IHC biomarkers are of significance – ER, 
PR, AR (all are top right in green), also PGP, cMET and ERCC1 (in red) – and in the plot shown below the EGFR sequencing marker 
stands out from the others, but is not statistically significant. In both plots, green dots indicate when the hazard rate of a positive biomarker 
result is significantly lower than that of a negative biomarker result, whereas a red dot is for when the hazard rate of a positive biomarker 
result is significantly higher than that of a negative biomarker result; grey dots denote when the difference between a positive and negative 
biomarker result is not significant.
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Figure 5: Further information about the estrogen receptor (ER) IHC biomarker, which was identified to be most prognostic for 
patient outcomes along with PR and AR. Upper left: ER is highly prognostic for ovarian surface epithelial cancer and breast cancer, as 
shown in this volcano plot. Upper right: a Kaplan-Meier plot for ER, i.e. those patients with a positive biomarker result have an improved 
outcome compared to those that do not, although this lessens in the long-term. Below: positive ratio for the ER IHC biomarker in different 
cancer cohorts within the Caris data i.e. the percentage in each cohort that have a positive biomarker result, when measuring protein 
expression above a predefined threshold. 
Figure 6: Information about the progesterone receptor (PR) biomarker, which was found to be most prognostic for patient outcomes 
along with ER and AR. Upper left: PR is highly prognostic for ovarian surface epithelial cancer, breast cancer and female genital tract malignancy. 
Upper right: a Kaplan-Meier plot for PR that shows that patients with a positive biomarker result have an improved outcome. Below: the percentage 
in each cohort that have a positive PR biomarker result (blue is positive).
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are still significant predictors of importance, but AR is no 
longer a significant predictor of outcome.
DISCUSSION
This report looked at clinical outcomes for a 
range of tumor type cohorts that were profiled by Caris 
Life Sciences to predict treatments using an algorithm. 
Treatments after tumor profiling were classed as matched 
or unmatched, according to if the drugs given by their 
doctor agreed with the recommendations that had utilized 
the molecular profile of their tumor. 
The unmatched group received more treatments in 
general than the matched group, and had a poorer survival 
prognosis. This could have been due to the unmatched 
group having tumors that were more advanced in stage 
than in the matched group, as shown in Table 5.
The survival curves diverge after the time of 
profiling (Figure 3), which could indicate that therapy 
predictions had an effect on improving outcome, due 
Figure 7: Plots for the androgen receptor (AR) biomarker, which was indicated to be significantly prognostic for 
patient outcomes along with ER and PR. Upper left: AR is highly prognostic for breast cancer, as shown in this volcano plot. Upper 
right: a Kaplan-Meier plot for PR where patients positive for AR have an improved outcome, although this narrows over the long-term. 
Below: the percentage in each cohort that have a positive AR biomarker result (blue is positive)
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to selection of optimal therapies. We see three IHC 
biomarkers being prognostic for poorer outcomes across 
the cohort (PGP, cMET and ERCC1) and suggest that 
these are further evaluated in prospective cohorts. 
Combined with the reduction in mortality, this indicates 
that there is a benefit from tumor molecular profiling 
here. This may be that part of this is due to the profiles 
uncovering the group of ER, PR and AR positive tumors 
that are generally associated with a better outcome.
We also found that the more time that patients 
received overlapping therapies, the more their survival 
time improved, in general.
MATERIALS AND METHODS
The Caris CODE database contains tumor molecular 
profile data for 841 patients with solid tumors (CODE 
version 1.0). It also includes demographic information 
about these patients, the drug treatments that they received 
before and after molecular profiling, and records of their 
clinical outcomes while they were still being monitored. 
This data was mined after web scraping the data from the 
Caris website, to understand if molecular characterization 
affected drug selection by treating physicians, and if any 
subtypes of molecular subsets had different outcomes 
across tumor types. Tables 1 and 2 describe the clinical 
characteristics of the patients that were profiled.
The amount of time that patients were monitored 
varied, as shown in Figure 1. On average patients’ 
treatment records were available for 1018 days after 
diagnosis (1034 days for matched treatment patients and 
1001 days for unmatched patients). On average the time 
of monitoring after profiling was 491 days, and the longest 
period of monitoring after profiling was 1906 days (the 
patient represented on the furthest right of Figure 1); this 
was 1920 days after diagnosis. The longest that records 
were available for any patient i.e. from diagnosis up until 
the last day of contact, was 12,537 days.
Abbreviations
American Society of Clinical Oncology 
(ASCO) CODE (Comprehensive Oncology Database 
Explorer); EGFR (epidermal growth factor receptor); 
immunohistochemistry (IHC); estrogen receptor (ER); 
Oncology Research Information Exchange Network 
(ORIEN); P-glycoprotein (PGP); progesterone receptor 
(PR); tyrosine-protein kinase Met (cMET).
Table 5: Matched and unmatched groups compared against all
Group Average Age Ethnicity Grade Stage
Survival 
(Days) Mortality
All patients 
(841)
61.5 White: 721; Black/African 
American: 70;
Asian: 25; Hawaiian/Pacific 
Islander: 11;
Other/unknown: 11;
American Indian/Alaskan 
Native: 3
Grade 4/Undifferentiated: 35 (4%);
Grade 3/Poorly
differentiated: 433 (51%);
Grade 2/Moderately differentiated: 
232 (28%);
Grade 1/Well differentiated: 41 
(5%);
Unknown/Not determined: 77 (9%);
None/Not applicable: 16 (2%);
High Grade: 6 (1%);
Low Grade: 1 (-%)
IV: 223 (27%);
III no IIIC: 136 (16%);
IIIC: 180 (21%);
II: 134 (16%);
I: 100 (12%);
Unknown: 68 (8%)
491 40%
Matched 
only (438)
61.6 White: 372; Black/African 
American: 33;
Asian: 16; Hawaiian/Pacific 
Islander: 8;
Other/unknown: 8;
American Indian/Alaskan 
Native: 1
Grade 4/Undifferentiated: 17 (4%);
Grade 3/Poorly differentiated: 224 
(51%);
Grade 2/Moderately differentiated: 
125 (29%);
Grade 1/Well differentiated: 23 
(5%);
Unknown/Not determined: 39 (9%);
None/Not applicable: 7 (2%);
High Grade: 2 (-%);
Low Grade: 1 (-%)
IV: 102 (23%);
III no IIIC: 74 (17%);
IIIC: 95 (22%);
II: 69 (16%);
I: 60 (14%);
Unknown: 38 (8%)
512 34%
Unmatched 
(403)
61.3 White: 349; Black/African 
American: 37;
Asian: 9; Hawaiian/Pacific 
Islander: 3;
Other/unknown: 3;
American Indian/Alaskan 
Native: 2 
Grade 4/Undifferentiated: 18 (4%);
Grade 3/Poorly differentiated: 209 
(52%);
Grade 2/Moderately differentiated: 
107 (27%);
Grade 1/Well differentiated: 18 
(4%);
Unknown/Not determined: 38 
(10%);
None/Not applicable: 9 (2%);
High Grade: 4 (1%)
IV: 121 (30%);
III no IIIC: 62 (15%);
IIIC: 85 (21%);
II: 65 (16%);
I: 40 (10%);
Unknown: 30 (8%)
468 47%
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